Fred Saad

Fred Saad is an internationally recognized prostate cancer specialist and principal investigator of the ARAMIS trial, which demonstrated that darolutamide significantly prolonged metastasis-free survival in nmCRPC patients. He is a professor of urology at the University of Montreal and has led numerous landmark clinical trials in advanced prostate cancer. His research encompasses novel androgen receptor inhibitors, bone-targeted therapies, and treatment sequencing strategies. Saad has co-authored over 300 peer-reviewed publications and is a frequent speaker at major oncology congresses.